University of California Los Angeles-ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2022

  1. Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 9, pp. 1854-1862

2020

  1. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in Neomonarch, phase II neoadjuvant study in HR+/HER2- Breast cancer

    Clinical Cancer Research, Vol. 26, Núm. 3, pp. 566-580

  2. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

    Annals of Oncology, Vol. 31, Núm. 11, pp. 1526-1535

2018

  1. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: Results from the PALOMA-2 trial

    Annals of Oncology, Vol. 29, Núm. 4, pp. 888-894

  2. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial

    Annals of Oncology, Vol. 29, Núm. 9, pp. 1939-1947

  3. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation

    New England Journal of Medicine, Vol. 379, Núm. 8, pp. 753-763

2016

  1. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial

    Annals of Oncology, Vol. 27, Núm. 6, pp. 1041-1047

2015

  1. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer

    Journal of Clinical Oncology, Vol. 33, Núm. 2, pp. 141-148

2012

  1. Analysis of Fcγ receptor IIIa and IIa polymorphisms: Lack of correlation with outcome in trastuzumab-treated breast cancer patients

    Clinical Cancer Research, Vol. 18, Núm. 12, pp. 3478-3486

2011

  1. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study

    The Lancet Oncology, Vol. 12, Núm. 4, pp. 369-376

  2. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

    Journal of Clinical Oncology, Vol. 29, Núm. 29, pp. 3877-3884

2003

  1. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial

    Journal of Clinical Oncology, Vol. 21, Núm. 6, pp. 968-975